Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,778 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the transaction, the director owned 2,778 shares in the company, valued at $326,553.90. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Simon Read also recently made the following trade(s):

• On Monday, August 10th, Simon Read sold 2,777 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $109.55, for a total transaction of $304,220.35.

Dianthus Therapeutics Price Performance

DNTH traded down $1.84 on Wednesday, reaching $113.70. 793,226 shares of the company traded hands, compared to its average volume of 959,581. The stock’s 50 day moving average price is $98.77 and its 200-day moving average price is $83.98. Dianthus Therapeutics, Inc. has a 52-week low of $22.06 and a 52-week high of $117.88. The company has a market cap of $6.22 billion, a price-to-earnings ratio of -27.40 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares during the last quarter. UBS Group AG increased its stake in shares of Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after purchasing an additional 469,547 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after purchasing an additional 441,156 shares during the period. SummitTX Capital L.P. lifted its position in shares of Dianthus Therapeutics by 13.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after purchasing an additional 12,118 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Dianthus Therapeutics by 155.5% during the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after purchasing an additional 24,697 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial lifted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.